On Monday, Mersana Therapeutics Inc (NASDAQ: MRSN) was -6.91%% drop from the session before settling in for the closing price of $0.37. A 52-week range for MRSN has been $0.26 – $2.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2.74%. When this article was written, the company’s average yearly earnings per share was at -6.99%. With a float of $96.84 million, this company’s outstanding shares have now reached $124.63 million.
Let’s determine the extent of company efficiency that accounts for 102 employees. In terms of profitability, gross margin is 100.0%, operating margin of -225.98%, and the pretax margin is -216.41%.
Mersana Therapeutics Inc (MRSN) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Mersana Therapeutics Inc stocks. The insider ownership of Mersana Therapeutics Inc is 22.30%, while institutional ownership is 50.18%. The most recent insider transaction that took place on Jan 16 ’25, was worth 2,061. In this transaction VP, Chief Accounting Officer of this company sold 3,554 shares at a rate of $0.58, taking the stock ownership to the 57,519 shares. Before that another transaction happened on Jan 16 ’25, when Company’s Director sold 8,637 for $0.58, making the entire transaction worth $5,009. This insider now owns 168,041 shares in total.
Mersana Therapeutics Inc (MRSN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -6.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.65% during the next five years compared to 2.74% growth over the previous five years of trading.
Mersana Therapeutics Inc (NASDAQ: MRSN) Trading Performance Indicators
You can see what Mersana Therapeutics Inc (MRSN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.83. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.60, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Mersana Therapeutics Inc (MRSN)
Looking closely at Mersana Therapeutics Inc (NASDAQ: MRSN), its last 5-days average volume was 1.51 million, which is a drop from its year-to-date volume of 4.29 million. As of the previous 9 days, the stock’s Stochastic %D was 10.43%.
During the past 100 days, Mersana Therapeutics Inc’s (MRSN) raw stochastic average was set at 14.62%, which indicates a significant increase from 7.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.44% in the past 14 days, which was lower than the 112.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3598, while its 200-day Moving Average is $1.1214. However, in the short run, Mersana Therapeutics Inc’s stock first resistance to watch stands at $0.3624. Second resistance stands at $0.3843. The third major resistance level sits at $0.3999. If the price goes on to break the first support level at $0.3249, it is likely to go to the next support level at $0.3093. Now, if the price goes above the second support level, the third support stands at $0.2874.
Mersana Therapeutics Inc (NASDAQ: MRSN) Key Stats
There are 124,631K outstanding shares of the company, which has a market capitalization of 42.45 million. As of now, sales total 40,500 K while income totals -69,190 K. Its latest quarter income was 2,750 K while its last quarter net income were -24,120 K.
